Literature DB >> 20807153

Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma.

M C Tavera1, P P Bassareo, P Neroni, C Follese, D Manca, S Montis, R Tumbarello.   

Abstract

Supraventricular tachycardia (SVT), being atrioventricular reentry the underlying mechanism, is the most frequently tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20807153     DOI： 10.3109/14767058.2010.509915

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN： 1476-4954


  4 in total

1.  Cardiogenic shock in a neonate.

Authors:  Eulália Viveiros; Ana Cristina Aveiro; Edite Costa; José Luis Nunes
Journal:  BMJ Case Rep       Date:  2013-06-03

2.  Stability of propranolol in extemporaneously compounded suspensions.

Authors:  Mary H H Ensom; Jennifer Kendrick; Susan Rudolph; Diane Decarie
Journal:  Can J Hosp Pharm       Date:  2013-03

3.  Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.

Authors:  Guglielmo Capponi; Gilda Belli; Mattia Giovannini; Giulia Remaschi; Alice Brambilla; Francesca Vannuccini; Silvia Favilli; Giulio Porcedda; Luciano De Simone
Journal:  BMC Cardiovasc Disord       Date:  2021-03-15       Impact factor: 2.298

Review 4.  Neonatal supraventricular tachyarrhythmias, approach and treatment from pathophysiology

Authors:  Keerby Hernández; Ángela Hoyos; Lina P Montana; María J Castellanos; Isabel Sánchez
Journal:  Arch Cardiol Mex       Date:  2022-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.